Experience the most advanced weight loss treatment ever developed. Retatrutide's revolutionary triple agonist technology delivers up to 24% body weight reduction - surpassing all previous medications.
Retatrutide represents the next evolution in weight loss medicine - a groundbreaking triple agonist that activates three metabolic pathways simultaneously.
Reduces appetite, slows gastric emptying, and improves blood sugar control - the same mechanism as Semaglutide (Ozempic).
Enhances insulin secretion and fat metabolism - combined with GLP-1 in Tirzepatide (Mounjaro), but Retatrutide adds more.
The breakthrough component. Increases energy expenditure and promotes fat burning - making Retatrutide uniquely powerful.
Previous weight loss medications targeted one or two pathways. Retatrutide is the first to activate all three major metabolic receptors, creating a synergistic effect that produces unprecedented results.
Clinical trials show Retatrutide achieves weight loss results that exceed both Semaglutide and Tirzepatide.
See how Ghana's most advanced weight loss treatment compares to previous generation medications.
| Feature | Semaglutide (Ozempic/Wegovy) |
Tirzepatide (Mounjaro) |
Retatrutide (Triple Agonist) |
|---|---|---|---|
| Mechanism | GLP-1 only Single agonist |
GLP-1 + GIP Dual agonist |
GLP-1 + GIP + Glucagon Triple agonist |
| Avg. Weight Loss | 15-17% | 20-22% | Up to 24% |
| Fat Burning | Moderate | Good | Superior (Glucagon effect) |
| Metabolic Rate | Unchanged | Slightly increased | Significantly increased |
| Injection Frequency | Weekly | Weekly | Weekly |
| Generation | 1st Gen | 2nd Gen | 3rd Gen - Latest |
Clinical studies show up to 24% total body weight reduction - the highest ever recorded for any weight loss medication.
The glucagon component actively increases your metabolic rate, burning more calories even at rest.
Be among the first in Ghana to access the newest, most advanced weight loss technology available anywhere in the world.
Phase 2 clinical trial data shows Retatrutide delivers unprecedented weight loss outcomes.
Starting dose. Appetite reduction begins. 2-4% weight loss typical.
Dose escalation. Significant weight loss. 8-12% reduction.
Maintenance dose reached. Steady progress. 15-20% total loss.
Peak results. Up to 24% total weight loss achieved.
Access Ghana's most advanced weight loss treatment with doctor supervision included.
Triple Agonist Formula
4-week supply with consultation
Free consultation. No obligation to proceed.
Nationwide delivery available. Contact us for other locations.
Join the future of weight loss medicine. Free consultation with our medical team - no obligation to proceed.
Start Free Consultation on WhatsAppAvailable in Accra, Kumasi, Takoradi, and nationwide delivery